Anti-CD20 Monoclonal Antibody MIL62 clinical trials
Also written MIL62.
Its developmentBy Beijing Mabworks Biotech and InnoCare Pharma, step by step10 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CD20 Monoclonal Antibody MIL62 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD20 Monoclonal Antibody MIL62 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Beijing Mabworks Biotech Co., Ltd. (8) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Chinese PLA General Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Anti-CD20 Monoclonal Antibody MIL62 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated GlomerulonephritisRecruitingPhase 2Chinese PLA General HospitalNCT07746180Written as Obinutuzumab beta
- A Phase 3 Clinical Study of MIL62 in Systemic Lupus ErythematosusRecruitingPhase 3Beijing Mabworks Biotech Co., Ltd.NCT07405970Written as MIL62
- MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)RecruitingPhase 1/2Beijing Mabworks Biotech Co., Ltd.NCT04110301Written as Recombinant Humanized Monoclonal Antibody MIL62 Injection
- A Phase 2 Clinical Study of MIL62 in Systemic Lupus ErythematosusCompletedPhase 2Beijing Mabworks Biotech Co., Ltd.NCT05796206Written as MIL62
- A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous NephropathyCompletedPhase 1/2Beijing Mabworks Biotech Co., Ltd.NCT05398653Written as MIL62
- A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)Active, not recruitingPhase 3Beijing Mabworks Biotech Co., Ltd.NCT05314010Written as MIL62
- A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous NephropathyActive, not recruitingPhase 3Beijing Mabworks Biotech Co., Ltd.NCT05862233Written as MIL62
- Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus NephritisActive, not recruitingPhase 1/2Beijing Mabworks Biotech Co., Ltd.NCT07044115Written as Recombinant Humanized Monoclonal Antibody MIL62 Injection
- A Study of MIL62 in Treatment of CD20 Positive B-cell LymphomasCompletedPhase 1Beijing Mabworks Biotech Co., Ltd.NCT04103905Written as Recombinant Humanized Monoclonal Antibody MIL62 Injection
- A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaActive, not recruitingPhase 1/2Beijing InnoCare Pharma Tech Co., Ltd.NCT04304040Written as Recombinant humanized monoclonal antibody MIL62 injection